BRPI0408733A - derivação de neurÈnios dopaminérgicos terminalmente diferenciados de células tronco embriÈnicas humanas - Google Patents

derivação de neurÈnios dopaminérgicos terminalmente diferenciados de células tronco embriÈnicas humanas

Info

Publication number
BRPI0408733A
BRPI0408733A BRPI0408733-0A BRPI0408733A BRPI0408733A BR PI0408733 A BRPI0408733 A BR PI0408733A BR PI0408733 A BRPI0408733 A BR PI0408733A BR PI0408733 A BRPI0408733 A BR PI0408733A
Authority
BR
Brazil
Prior art keywords
cells
human embryonic
dopaminergic neurons
terminally differentiated
derivation
Prior art date
Application number
BRPI0408733-0A
Other languages
English (en)
Inventor
Satish Totey Mahadeorao
Geeta Ravindran
Original Assignee
Reliance Life Sciences Pvt Ltd
Satish Totey Mahadeorao
Geeta Ravindran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliance Life Sciences Pvt Ltd, Satish Totey Mahadeorao, Geeta Ravindran filed Critical Reliance Life Sciences Pvt Ltd
Publication of BRPI0408733A publication Critical patent/BRPI0408733A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"DERIVAçãO DE NEURÈNIOS DOPAMINéRGICOS TERMINALMENTE DIFERENCIADOS DE CéLULAS TRONCOS EMBRIÈNICAS HUMANAS". Compreendendo métodos aperfeiçoados para a produção eficaz de células neuroprogenitoras e células neurais diferenciadas, tais como neurónios dopaminérgicos e neurónios serotonérgicos de células tronco pluripotentes, por exemplo, células tronco embriónicas humanas. Através da utilização dos métodos apresentados, foram isoladas populações de células contendo uma grande proporção de células positivas para a tirosina hidroxilase, um marcador específico para neurónios dopaminérgicos. As células neuroprogenitoras e as células terminalmente diferenciadas da presente invenção podem ser geradas em grandes quantidades, e portanto podem servir como uma excelente fonte para a terapia de substituição de células em distúrbios neurolócicos, tal como o mal de Parkinson.
BRPI0408733-0A 2003-03-12 2004-03-11 derivação de neurÈnios dopaminérgicos terminalmente diferenciados de células tronco embriÈnicas humanas BRPI0408733A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN269MU2003 2003-03-12
US52004803P 2003-11-14 2003-11-14
PCT/IB2004/001246 WO2004081172A2 (en) 2003-03-12 2004-03-11 Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells

Publications (1)

Publication Number Publication Date
BRPI0408733A true BRPI0408733A (pt) 2006-03-07

Family

ID=32992649

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408733-0A BRPI0408733A (pt) 2003-03-12 2004-03-11 derivação de neurÈnios dopaminérgicos terminalmente diferenciados de células tronco embriÈnicas humanas

Country Status (10)

Country Link
US (1) US7674620B2 (pt)
EP (1) EP1613726A4 (pt)
JP (1) JP2010187669A (pt)
KR (1) KR100763477B1 (pt)
AU (1) AU2004219851B2 (pt)
BR (1) BRPI0408733A (pt)
CA (1) CA2518577A1 (pt)
IL (1) IL170788A (pt)
RU (1) RU2345133C2 (pt)
WO (1) WO2004081172A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588937B2 (en) 2001-10-03 2009-09-15 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US8153424B2 (en) 2001-10-03 2012-04-10 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
CA2489206C (en) * 2002-06-24 2012-08-07 Tanabe Seiyaku Co., Ltd. Method for producing neural cell
WO2004009758A2 (en) * 2002-07-23 2004-01-29 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
AU2005264579B2 (en) 2004-07-22 2010-06-10 Eisai R&D Management Co., Ltd. Lrp4/Corin dopaminergic neuron progenitor cell markers
US20060069008A1 (en) 2004-09-28 2006-03-30 Sanjay Mistry Treatment of neurological deficits in the striatum or substanta nigra pars compacta
CA2583473A1 (en) * 2004-10-05 2007-04-04 University Of Georgia Research Foundation, Inc. Neuronal progenitors from feeder-free human embryonic stem cell culture
US8597947B2 (en) * 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
EP2410043A3 (en) * 2004-12-29 2013-01-23 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
EP1856248A4 (en) * 2005-02-09 2010-01-20 Burnham Inst Medical Research HOMOGENEOUS NEURALE CURRENT CELLS
WO2007020655A1 (en) * 2005-05-17 2007-02-22 Reliance Life Sciences Pvt Ltd Establishment of a human embryonic stem cell line using mammalian cells
KR100683198B1 (ko) * 2006-01-09 2007-02-15 주식회사 휴림바이오셀 신경전구세포를 도파민성 신경세포로 분화시키는 방법 및그에 사용되는 배지
CN103893211A (zh) * 2006-03-07 2014-07-02 吉塔·什罗夫 包含人胚胎干细胞和其衍生物的组合物、其使用方法和制备方法
US20100297087A1 (en) * 2006-04-11 2010-11-25 Nanodiagnostics Israel., Ltd Pluripotent stem cells characterized by expression of germline specific genes
WO2008132722A1 (en) 2007-04-26 2008-11-06 Ramot At Tel-Aviv University Ltd. Pluripotent autologous stem cells from oral mucosa and methods of use
US20100291042A1 (en) * 2007-05-03 2010-11-18 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
ES2537578T3 (es) * 2007-07-18 2015-06-09 Lifescan, Inc. Diferenciación de las células madre de embriones humanos
DE102007044487A1 (de) * 2007-09-18 2009-04-02 Universität Leipzig Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe
KR20090069514A (ko) * 2007-12-26 2009-07-01 경상대학교산학협력단 벤트랄 중뇌 내 티로신 하이드록실라제 및 Νｕｒｒ1 발현증강제로서 비타민 Ｃ 및 비타민 Ｅ
US10227563B2 (en) * 2008-06-06 2019-03-12 Riken Method for culture of stem cell
KR101651661B1 (ko) * 2008-06-30 2016-08-26 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
US10793830B2 (en) 2009-11-05 2020-10-06 Riken Method for producing retinal tissue in vitro
WO2011108766A1 (en) * 2010-03-03 2011-09-09 Kyoto University METHOD FOR DIAGNOSING A PROTEIN MISFOLDING DISEASE USING NERVE CELLS DERIVED FROM iPS CELLS
JP5784296B2 (ja) * 2010-10-01 2015-09-24 学校法人 創価大学 神経細胞の製造方法及び神経細胞分化促進剤
WO2012135621A2 (en) 2011-03-30 2012-10-04 Cellular Dynamics International. Inc Priming of pluripotent stem cells for neural differentiation
JP6090937B2 (ja) 2011-07-27 2017-03-08 国立大学法人京都大学 新規ドーパミン産生神経前駆細胞マーカー
EP2782587B1 (en) 2011-11-21 2018-11-07 Ramot at Tel Aviv University, Ltd. Stem cell-derived neural cells for cell therapy in neurological disorders
RU2505602C1 (ru) * 2012-06-04 2014-01-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Способ получения резидентных стволовых клеток сердца млекопитающего из образцов миокарда
NZ716812A (en) 2013-08-06 2022-04-29 Takeda Pharmaceuticals Co Method for producing dopaminergic neurons
CN105849255A (zh) 2013-09-05 2016-08-10 国立大学法人京都大学 新的产多巴胺神经前体细胞诱导方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
CN107072716A (zh) 2014-05-30 2017-08-18 托德.F.奥沃凯蒂斯 用于产生和使用活化的干细胞的方法和系统
WO2015187974A1 (en) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Methods and compositions for increasing the bioactivity of nutrients
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
SG11201806557VA (en) * 2016-01-22 2018-08-30 Univ Nagoya Nat Univ Corp Differentiation induction from human pluripotent stem cells into hypothalamic neurons
KR102680159B1 (ko) 2016-03-06 2024-06-28 빈트플루스존네 게엠베하 음향 영동법에 의해 유체로부터 고체 물질 입자 및 섬유, 및 가스로부터 에어로졸 및 고체 물질 입자 및 섬유를 분리하고/하거나 세정하기 위한 방법 및 장치
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
CN106497879A (zh) * 2016-11-07 2017-03-15 广州赛莱拉干细胞科技股份有限公司 一种神经干细胞增殖和诱导其分化为多巴胺能神经元的培养基以及应用和增殖诱导方法
RU2690498C1 (ru) * 2018-05-17 2019-06-04 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Способ получения ноотропной композиции на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека
RU2690846C1 (ru) * 2018-05-17 2019-06-06 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека
EP3851521A4 (en) * 2018-09-14 2022-06-29 Keio University Method for producing astrocytes
DE102018008259A1 (de) 2018-10-18 2020-04-23 Smart Material Printing B.V. Filteranlagen für Schwebstoffe mit Teilchengrößen von 400 pm bis ≤500 μm und ihre Verwendung
BR112022019060A2 (pt) 2020-03-25 2022-11-29 Sana Biotechnology Inc Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
AU2021397627A1 (en) 2020-12-08 2023-07-20 Todd Frank OVOKAITYS Methods and systems for increased production of stem cells
BR112023024434A2 (pt) 2021-05-27 2024-02-20 Sana Biotechnology Inc Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas
US11291939B1 (en) 2021-07-13 2022-04-05 Smart Material Printing B.V. Ultra-fine particle aggregation, neutralization and filtration
EP4370544A2 (en) 2021-07-14 2024-05-22 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
MX2024001443A (es) 2021-08-11 2024-05-15 Sana Biotechnology Inc Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
JP2024534771A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
US20240417682A1 (en) * 2021-10-15 2024-12-19 National Stem Cell Foundation Methods and systems for culturing organoids
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
US12005388B2 (en) 2022-07-26 2024-06-11 Smart Material Printing B.V. Apparatus and methods for air filtration of HVAC systems
CN116333979A (zh) * 2023-04-03 2023-06-27 潍坊吉涛医学科技有限公司 一种干细胞培养液及其制备方法
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514552A (en) 1993-04-30 1996-05-07 Arch Development Corporation Hybrid neuronal cell lines compositions and methods
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
DE19756864C5 (de) * 1997-12-19 2014-07-10 Oliver Brüstle Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
WO2001068815A1 (en) * 2000-03-14 2001-09-20 Es Cell International Pte Ltd Embryonic stem cells and neural progenitor cells derived therefrom
WO2001083715A2 (en) 2000-05-01 2001-11-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary, Derivation of midbrain dopaminergic neurons from embryonic stem cells
IL152741A0 (en) 2000-05-17 2003-06-24 Geron Corp Neural progenitor cell populations
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
AU2002307455A1 (en) 2001-04-20 2002-11-05 Memorial Sloan-Kettering Cancer Center Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use
IL160351A0 (en) 2001-08-23 2004-07-25 Reliance Life Sciences Pvt Ltd ISOLATION OF INNER CELL MASS FOR THE ESTABLISHMENT OF HUMAN EMBRYONIC STEM CELL (hESC) LINES
US6887706B2 (en) 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
EP2360241A1 (en) 2002-06-05 2011-08-24 ES Cell International Pte Ltd. Stem cells
US7390659B2 (en) 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof
EP1534068A4 (en) 2002-08-08 2006-08-23 Univ Georgia Res Found COMPOSITIONS AND METHODS FOR NEURALE DIFFERENTIATION OF EMBRYOSTAMIC CELLS

Also Published As

Publication number Publication date
WO2004081172A3 (en) 2006-04-06
US7674620B2 (en) 2010-03-09
AU2004219851B2 (en) 2009-12-17
IL170788A (en) 2010-11-30
WO2004081172A2 (en) 2004-09-23
EP1613726A4 (en) 2007-08-22
CA2518577A1 (en) 2004-09-23
RU2005131581A (ru) 2006-04-27
RU2345133C2 (ru) 2009-01-27
US20060211109A1 (en) 2006-09-21
JP2010187669A (ja) 2010-09-02
KR20060010725A (ko) 2006-02-02
AU2004219851A1 (en) 2004-09-23
EP1613726A2 (en) 2006-01-11
KR100763477B1 (ko) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2004081172A3 (en) Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells
Bellenchi et al. Adult neural stem cells: an endogenous tool to repair brain injury?
Nandoe Tewarie et al. Stem cell-based therapies for spinal cord injury
Conover et al. Aging of the subventricular zone neural stem cell niche
KR101816103B1 (ko) 소분자 화합물을 이용한 인간 섬유아세포를 신경줄기세포로 직접 전환하는 방법
WO2005021704A3 (en) In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders
GB2452667A (en) Efficient generation of neural progenitors, neurons and dopaminergic neurons from human embryonic stem cells
MX2009005496A (es) Uso de una composicion que contiene una celula madre mesenquimal derivada de sangre del cordon umbilical humano para inducir diferenciacion y proliferacion de celulas precursoras neurales o celulas madre neurales a celulas neurales.
Zhou et al. Epigenetic regulations in neural stem cells and neurological diseases
Kwon et al. Vertical nanowire electrode array for enhanced neurogenesis of human neural stem cells via intracellular electrical stimulation
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
GT200200039A (es) Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos
Lestrell et al. Vertically aligned nanostructured topographies for human neural stem cell differentiation and neuronal cell interrogation
EP1402005A4 (en) A method of purification of cells
DE60120682D1 (de) Therapeutische verwendung mesenchymaler stromazellen
Luo et al. Optogenetic Modulation and Reprogramming of Bacteriorhodopsin‐Transfected Human Fibroblasts on Self‐Assembled Fullerene C60 Nanosheets
Li et al. Effect of light emitting diode irradiation on proliferation of human bone marrow mesenchymal stem cells
DK1745069T3 (da) Terapeutisk anvendelse af vækstfaktoren NSG33
WO2004053084A3 (en) Dopaminergic neurons differentiated from embryonic cells for treating neurodegenerative diseases
WO2006086746A3 (en) Homogeneous neural precursor cells
Daadi Differentiation of neural stem cells derived from induced pluripotent stem cells into dopaminergic neurons
Tregub et al. Hypercapnia and hypoxia stimulate proliferation of astrocytes and neurons in vitro
Fricker-Gates et al. Stem cell-derived dopamine neurons for brain repair in Parkinson’s disease
Nie et al. Genetic screening of haploid neural stem cells reveals that Nfkbia and Atp2b4 are key regulators of oxidative stress in neural precursors
Tang et al. Potential Application of Electrical Stimulation in Stem Cell‐Based Treatment against Hearing Loss

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.